JP2013513625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013513625A5 JP2013513625A5 JP2012543426A JP2012543426A JP2013513625A5 JP 2013513625 A5 JP2013513625 A5 JP 2013513625A5 JP 2012543426 A JP2012543426 A JP 2012543426A JP 2012543426 A JP2012543426 A JP 2012543426A JP 2013513625 A5 JP2013513625 A5 JP 2013513625A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nefopam
- scar
- catenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 229960000751 nefopam Drugs 0.000 claims 9
- 231100000241 scar Toxicity 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 6
- 102000015735 Beta-catenin Human genes 0.000 claims 5
- 108060000903 Beta-catenin Proteins 0.000 claims 5
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- -1 nefopam compound Chemical class 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000893 fibroproliferative effect Effects 0.000 claims 3
- 206010023330 Keloid scar Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010039580 Scar Diseases 0.000 claims 2
- 206010016629 fibroma Diseases 0.000 claims 2
- 206010049444 fibromatosis Diseases 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000002390 hyperplastic effect Effects 0.000 claims 2
- 230000001969 hypertrophic effect Effects 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000016362 Catenins Human genes 0.000 claims 1
- 108010067316 Catenins Proteins 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010019043 Hair follicle tumour benign Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 208000016272 Ledderhose disease Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010062575 Muscle contracture Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000006111 contracture Diseases 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000001095 pilomatrixoma Diseases 0.000 claims 1
- 208000009975 plantar fibromatosis Diseases 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28663309P | 2009-12-15 | 2009-12-15 | |
| US61/286,633 | 2009-12-15 | ||
| PCT/CA2010/002014 WO2011072394A1 (en) | 2009-12-15 | 2010-12-15 | METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013513625A JP2013513625A (ja) | 2013-04-22 |
| JP2013513625A5 true JP2013513625A5 (enExample) | 2014-02-06 |
| JP5792185B2 JP5792185B2 (ja) | 2015-10-07 |
Family
ID=44166687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543426A Expired - Fee Related JP5792185B2 (ja) | 2009-12-15 | 2010-12-15 | 線維増殖性障害および癌からなる群から選択されるβ−カテニン媒介障害を治療するための医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8957107B2 (enExample) |
| EP (1) | EP2512468B1 (enExample) |
| JP (1) | JP5792185B2 (enExample) |
| KR (1) | KR101753439B1 (enExample) |
| CN (2) | CN105687185B (enExample) |
| BR (1) | BR112012014471A2 (enExample) |
| CA (1) | CA2782472C (enExample) |
| DK (1) | DK2512468T3 (enExample) |
| ES (1) | ES2594900T3 (enExample) |
| WO (1) | WO2011072394A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2512468B1 (en) * | 2009-12-15 | 2016-08-24 | The Hospital for Sick Children | METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS |
| US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
| WO2018223023A1 (en) * | 2017-06-02 | 2018-12-06 | Beta Cat Pharmaceuticals, Inc. | Methods for treatment of fibrotic diseases |
| US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| US11266637B2 (en) * | 2018-06-01 | 2022-03-08 | Iterion Therapeutics, Inc. | Formulations of tegavivint and related compounds |
| CN110638780A (zh) * | 2019-09-11 | 2020-01-03 | 华益药业科技(安徽)有限公司 | 一种盐酸奈福泮片及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US6630142B2 (en) | 1999-05-03 | 2003-10-07 | Zymogenetics, Inc. | Method of treating fibroproliferative disorders |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| US20030190308A1 (en) * | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
| GB0213869D0 (en) * | 2002-06-17 | 2002-07-31 | Arakis Ltd | The treatment of pain |
| US20060019940A1 (en) | 2002-12-20 | 2006-01-26 | Baxter Andrew D | Novel benzoxazocines and their therapeutic use |
| BR0317467A (pt) | 2002-12-20 | 2005-11-16 | Arakis Ltd | Benzoxazocinas e seu uso como inibidores de reassimilação de monoaminas |
| GB0330049D0 (en) | 2003-12-24 | 2004-02-04 | Arakis Ltd | The treatment of neuropathic pain conditions |
| JP2007533718A (ja) | 2004-04-21 | 2007-11-22 | ソセイ・アール・アンド・ディー・リミテッド | ベンゾオキサゾシン類およびそれらのモノアミン再取込み阻害剤としての治療的使用 |
| GB2413322A (en) | 2004-04-21 | 2005-10-26 | Arakis Ltd | Nefopam analogues |
| CN1569004A (zh) * | 2004-05-13 | 2005-01-26 | 南昌弘益科技有限公司 | 盐酸奈福泮滴丸及其制备方法 |
| FR2880275B1 (fr) | 2005-01-06 | 2007-04-13 | Biocodex | Utilisation de composes pharmacologiques pour la prevention ou le traitement de la tolerance aigue aux morphiniques |
| GB0506835D0 (en) * | 2005-04-04 | 2005-05-11 | Arakis Ltd | Therapeutic use of nefopam |
| GB0515703D0 (en) | 2005-07-29 | 2005-09-07 | Arakis Ltd | Therapeutic use of nefopam |
| CN101002756A (zh) | 2007-01-19 | 2007-07-25 | 陶燃 | 盐酸奈福泮的透皮贴片制剂 |
| GB0721013D0 (en) | 2007-10-25 | 2007-12-05 | Sosei R & D Ltd | New Salts |
| US8158367B2 (en) | 2008-06-16 | 2012-04-17 | Academia Sinica | Cancer diagnosis based on levels of antibodies against Globo H and its fragments |
| GB2461874B (en) | 2008-07-14 | 2012-11-21 | Caltec Ltd | Separation system and method |
| FR2940911B1 (fr) * | 2009-01-13 | 2012-09-21 | Philippe Perovitch | Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques |
| EP2512468B1 (en) * | 2009-12-15 | 2016-08-24 | The Hospital for Sick Children | METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS |
-
2010
- 2010-12-15 EP EP10836897.8A patent/EP2512468B1/en not_active Not-in-force
- 2010-12-15 WO PCT/CA2010/002014 patent/WO2011072394A1/en not_active Ceased
- 2010-12-15 KR KR1020127018272A patent/KR101753439B1/ko not_active Expired - Fee Related
- 2010-12-15 CN CN201610027616.7A patent/CN105687185B/zh not_active Expired - Fee Related
- 2010-12-15 CA CA2782472A patent/CA2782472C/en active Active
- 2010-12-15 BR BR112012014471A patent/BR112012014471A2/pt not_active Application Discontinuation
- 2010-12-15 DK DK10836897.8T patent/DK2512468T3/en active
- 2010-12-15 US US13/516,016 patent/US8957107B2/en active Active
- 2010-12-15 ES ES10836897.8T patent/ES2594900T3/es active Active
- 2010-12-15 JP JP2012543426A patent/JP5792185B2/ja not_active Expired - Fee Related
- 2010-12-15 CN CN201080057504.7A patent/CN102781442B/zh not_active Expired - Fee Related
-
2014
- 2014-12-19 US US14/577,329 patent/US9566263B2/en active Active
-
2016
- 2016-12-24 US US15/390,468 patent/US20170172980A1/en not_active Abandoned
-
2017
- 2017-05-19 US US15/599,516 patent/US10722493B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013513625A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| EP2032128B1 (en) | Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain | |
| JP2013507415A5 (enExample) | ||
| EA201171109A1 (ru) | Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| US8937063B2 (en) | Niacin mimetics, and methods of use thereof | |
| JP2016540738A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| CN111012785B (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途 | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| AU2011270726A1 (en) | Niacin mimetics, and methods of use thereof | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| NZ592615A (en) | Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| WO2006017816A3 (en) | Product and process for inhibition of biofilm development | |
| JP2009513713A5 (enExample) | ||
| WO2008092072A3 (en) | Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof | |
| JP2012508256A5 (enExample) | ||
| JP2015508765A5 (enExample) | ||
| TW200603816A (en) | Risedronate compositions and their methods of use | |
| JP2002534477A5 (enExample) | ||
| JP6116674B2 (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ−［３，４，ｂ］インドール］−４−アミンおよびプロピオン酸誘導体を含む医薬組成物 | |
| JP2008503504A5 (enExample) | ||
| JP2012525358A5 (enExample) |